NCT04120701View on ClinicalTrials.gov

CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,980

Participants

Timeline

Start Date

January 17, 2020

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Patients With Resected Stage II Colon Cancer
Interventions
DRUG

mFOLFOX6

Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).

Trial Locations (1)

21000

RECRUITING

Fédération Francophone de Cancérologie Digestive, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER